Immediate Release

DIMERIX TO PRESENT AT MELBOURNE TWILIGHT INVESTOR BRIEFING

MELBOURNE, Australia, 13 June 2024: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company with late-stage clinical assets, is pleased to advise that CEO and Managing Director, Dr Nina Webster, will be presenting at the Monsoon Twilight Investor Briefing in Melbourne on 13 June 2024.

Key points that will be covered:

- Phase 3 global clinical trial in FSGS kidney disease status and update
- Commercial partnering update
- Commercial opportunity and addressable market value

A copy of the presentation is attached.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
Mob: +61 (0)411 402 737
E: rudim@monsoon.com.au

Follow us on **LinkedIn** and **Twitter**

Authorised for lodgement by the Board of the Company

—END—

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. Dimerix is currently focussed on developing its proprietary Phase 3 product candidate DMX-200 (QYTOVRA® in some territories), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease, and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-700 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

About DMX 200

DMX 200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker - the standard of care treatment for hypertension and kidney disease. DMX 200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042, in addition to any exclusivity period that may apply in key territories. In 2020, Dimerix completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease, following a successful Phase 2a trial in patients with a range of chronic kidney diseases in 2017. No significant adverse safety events were reported in any trial, and all studies resulted in encouraging data that could provide meaningful clinical outcomes for patients with kidney disease.

About FSGS

FSGS is a rare disease that attacks the kidney's filtering units, where blood is cleaned (called the 'glomeruli'), causing irreversible scarring. This leads to permanent kidney damage and eventual end-stage failure of the organ, requiring dialysis or transplantation. For those diagnosed with FSGS the prognosis is not good. The average time from a diagnosis of FSGS to the onset of complete kidney failure is only five years and it affects both adults and children as young as two years old.[1] For those who are fortunate enough to receive a kidney transplant, approximately 60% will get re-occurring FSGS in the transplanted kidney.[2] At this time, there are no drugs specifically approved for FSGS anywhere in the world, so the treatment options and prognosis are limited.

FSGS is a billion-dollar plus market: the number of people with FSGS in the US alone is just over 80,000,[1] and worldwide about 220,000.[3] The illness has a global compound annual growth rate of 8%, with over 5,400 new cases diagnosed in the US alone each year.[4] Because there is no effective treatment, Dimerix has received Orphan Drug Designation for DMX 200 in both the US and Europe for FSGS. Orphan Drug Designation is granted to support the development of products for rare diseases and qualifies Dimerix for various development incentives including: seven years (FDA) and ten years (EMA) of market exclusivity if regulatory approval is received, exemption from certain application fees, and a fast-tracked regulatory pathway to approval. Dimerix reported positive Phase 2a data in FSGS patients in July 2020.

References

1 *Guruswamy Sangameswaran KD, Baradhi KM. (2021) Focal Segmental Glomerulosclerosis), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/*

2 *Front. Immunol., (July 2019) | https://doi.org/10.3389/fimmu.2019.01669*

3 *Delve Insight Market Research Report (2022): Focal segmental glomerulosclerosis (FSGS) – Market Insight, Epidemiology and market forecast – 2032; https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market;*

4 *Nephcure Kidney International (2020); Focal Segmental Glomerulosclerosis, online https://nephcure.org/livingwithkidneydisease/understanding-glomerular-disease/understanding-fsgs/*

Dimerix

(ASX:DXB)

ACTION3

FSGS CLINICAL STUDY



13 June 2024

Twilight Briefing

Developing new therapies to treat inflammatory causes of kidney and respiratory disease with unmet clinical needs

Authorised for lodgement by the Board of the Company

Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.

Corporate overview

Ticker Symbol	ASX: DXB
Proforma Cash Balance (Mar24)	~A$35.2 million
Market Capitalisation	~A$333 million
Share price	~A$0.605
Total ordinary shares on issue	549,742,608
Average Daily Liquidity by value[1]	~$4.0 million

SHARE PRICE

SUBSTANTIAL SHAREHOLDERS[2]

	Holder Name	Holding	
1	Mr P Meurs	75,304,506	13.7%
TOTAL (TOP 5)		124,446,381	22.6%

1. Past 30 trading days liquidity as at 12 June 2024; 2. Shareholder register as at 12June 2024

Overview | Phase 3 Global Opportunity

Lead Drug Candidate

- DMX-200 is currently in a **Phase 3 clinical trial** for focal segmental glomerulosclerosis (FSGS)
- DMX-200 has **orphan drug designation** in key territories

FSGS Indication

- FSGS is a **rare disease** that causes scar tissue of kidneys, which leads to irreversible kidney damage[1]
- FSGS kidney damage can lead to dialysis, kidney transplants or death[1]
- There are currently **no approved treatments** available to treat FSGS

Commercial Validation

- **Two commercial licensing deals** achieved:
  - ~AU$11.5m in upfront payments, ~AU$340m in potential milestone payments + tiered royalties[2]
- **Successful Phase 3 interim analysis**: DMX-200 is performing better than placebo in reducing proteinuria[3]

Dimerix

1. Guruswamy Sangameswaran KD, Baradhi KM. Focal Segmental Glomerulosclerosis (July 2021), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/; 2. ASX release 05 October 2023 and 27 May 2024; 3. Predictive Power statistical model, using industry standard as set by the independent renal biostatistician consultant for Dimerix

Focal Segmental Glomerulosclerosis (FSGS)

What is FSGS?

Focal	= some
Segmental	= sections
Glomerulo	= of the kidney filtering units
Sclerosis	= are scarred

Why are kidneys important?

A healthy kidney is a good filter and allows little to no protein in the urine[2]

Inside a *healthy* kidney



Inside a *damaged* kidney



● = Protein
(protein in the urine = proteinuria)



Healthy kidney: blood is effectively filtered creating urine

FSGS kidney: scarring impacts kidney function

Why is proteinuria important?

When kidneys are damaged, protein can leak into the urine causing proteinuria, hence proteinuria can represent an important early marker of kidney function[1]

▲ proteinuria suggests damaged kidney

▼ little / no proteinuria suggests healthy kidney

DMX-200 aims to reduce the inflammation of the kidneys:
if DMX-200 reduces inflammation = the amount of proteinuria should decrease
Proteinuria: an important endpoint for DMX-200 study

Dimerix

1. Guruswamy Sangameswaran KD, Baradhi KM. Focal Segmental Glomerulosclerosis (July 2021), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/;
2. Nephcure FSGS living with the disease (2024) at https://nephcure.org/livingwithkidneydisease/ns-and-other-glomerular-diseases/understanding-fsgs/

Progression of FSGS kidney disease



1. Lewis, E. J. et al. (2001), New Engl J Medicine 345, 851–860; 2. Ayoub MA, et al. (2015) PLoS ONE 10(3): e0119803

DMX-200: Phase 2 met primary and secondary endpoints

Clinically meaningful outcomes achieved for patients,[3] with no safety issues

Average reduction of **17%** in proteinuria after 16 weeks treatment on DMX-200 versus placebo[1]



"Any reduction in proteinuria could yield years of preserved native kidney function and delay the onset of kidney failure and its attendant morbidity and mortality"

Kidney survival study – Troost et al, August 2020[3]



EFFICACY

- **86%** of patients demonstrated reduced proteinuria
- DMX-200 reduced inflammatory biomarker by **39%** vs placebo

SAFETY

- No safety concerns – reduced development risk

Dimerix

PCR = protein creatinine ratio; ARB = angiotensin receptor blocker; 1. Repeated measures mixed model analysis; top line data was reported as grouped analysis; 2. Trachtman, et al., 2018. J Amer Soc Nephrology 29(11):2745-2754; 3. Troost JP et al (August 2020); doi.org/10.1053/j.ajkd.2020.04.014

DMX-200: Phase 2 met primary and secondary endpoints

17% average reduction of proteinuria in Phase 2 is clinically meaningful[1]



FDA & EMA recognise surrogate markers, such as proteinuria & EGFR as registration endpoints in rare kidney disease

"reductions ~10% in proteinuria translated to clinically meaningful differences in eGFR" Kidney survival study – Troost et al, August 2020[1]

uPCR = protein creatinine ratio; eGFR: estimated Glomerular Filtration Rate – measure of kidney function; 1. Troost JP et al (August 2020); doi.org/10.1053/j.ajkd.2020.04.014

PHASE 3 CLINICAL TRIAL



ACTION3 FSGS CLINICAL STUDY Phase 3 clinical trial – next steps

A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB

Background

- Patients recruited, then screened and stabilised on background medications
- Patients randomised to receive drug or placebo
- DXB remains blinded at all times during study

Phase 3 Trial Timeline



★ *Potential to submit for conditional marketing approval**

*subject to project PARASOL outcomes, recommendations of the IDMC (based on review of emerging data from ACTION3) and subsequent discussions with the appropriate regulatory authorities such as the FDA in the US.
uPCR = urinary proteinuria; eGFR = estimated glomerular filtration rate (kidney function);

Dimerix

ACTION3 current and planned clinical sites

FSGS CLINICAL STUDY

A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB

Recruitment planned at +170 sites in:

- Australia, New Zealand
- Taiwan, Hong Kong, Malaysia
- Mainland China
- France, Denmark, UK, Spain Italy, Germany, Portugal
- Türkiye
- USA, Mexico
- Argentina, Brazil



FSGS MARKET OPPORTUNITY

Potential FSGS market size

No approved therapies for FSGS

DMX-200 is the only therapy in phase 3 development

Multi-billion dollar market potential

- Example pricing for other rare kidney disease drugs :
  - in the US (i.e. Filspari in IgAN)[2] is **US$9,900 p/month**
  - in Europe/UK (i.e. Kinpeygo/Tarpeyo)[3] is **US$8,267 p/month** (€7,630)
- Example annual pricing[2,3]:
  - ~**US$120k per annum** per patient for FSGS drug in US
  - ~**€91,560 per annum** per patient for FSGS drug in Europe
- **Strong upside** for all partnering outside of the 7MM/China

Estimated 7MM (+China) diagnosed patients (2022)[1,4]



Dimerix

1. Focal segmental glomerulosclerosis – Market Insight (2022), Epidemiology and market forecast – 2032 Delve Insight; 2. Cost of Sparsentan - approved for IgAN https://endpts.com/fda-clears-traveres-rare-kidney-disease-drug-will-come-with-rems-program; Cost of Tarpeyo Wholesale acquisition cost (WAC) of $14,160 for a 30-day supply/$170k /year https://www.calliditas.se/en/wp-content/uploads/sites/2/2018/01/fda-approval-webcast-presentation.pdf; 3. NICE recommends targeted-release budesonide for primary IgA nephropathy, Cost of Kinpeygo list price of €7,630 for a 30-day supply, https://doi.org/10.1002/psb.0010132; 4. Personal communication (2022) FSGS sales forecasts in China; 4. https://www.researchandmarkets.com/reports/5309873/focal-segmental-glomerulosclerosis-global;

Summary of DMX-200 licensing deals

Dimerix has validated the technology[1] and proven its ability to licence multiple territories, with more deals anticipated

Summary	ADVANZ PHARMA [2]	taiba access rare [3]	Other Licensing Deals (incl. US & China)
Territories Covered	EEA, Canada, Switzerland, UK, Australia and New Zealand	United Arab Emirates (UAE), Saudi Arabia, Oman, Kuwait, Qatar, Bahrain and Iraq	?
Upfront Payment	~AU$10.8 million	~AU$500,000	?
Milestone Payments	Up to ~AU$219 million	Up to ~AU$120 million	?
Royalties on net sales	Escalating mid-teen-20%	Starting at 30%	?

Dimerix has achieved up to AU$350 million[2,3] in upfront payments and potential milestones payments from two licensing deals

Major focus on US & China which, collectively, could represent ~70% of the global value[4]

1. ASX release 5 March 2024; 2. Based on Euro conversions & further terms outlined in ASX Announcement on 5 October 2023
3. Based on US dollar conversions & further terms outlined in ASX Announcement on 27 May 2024; 4. see slide 9

Global partnering availability

- Licensing deal second of potentially multiple agreements globally

- Received multiple non-binding term sheets for global deals and regional deals[1]
- Multiple parties in data room conducting due diligence and negotiating for various territories[1]



Major targets for DXB are US & China, with partnering discussions already underway

1. Offers are non-binding and subject to due diligence, an agreed definitive agreement and board approval

Summary | Phase 3 Global Opportunity



Lead Drug Candidate ✓	• DMX-200 is currently in a **Phase 3 clinical trial** for focal segmental glomerulosclerosis (FSGS)
FSGS Indication ✓	• FSGS is a disease that causes scar tissue of kidneys, which leads to irreversible kidney damage[1] • FSGS kidney damage can lead to dialysis, kidney transplants or death[1]
Market Opportunity ✓	• Estimated ~>200,000 people with FSGS in the 7 major markets (makes **FSGS a rare disease**)[2] • Estimated 40,000[1] – 80,000[2] people in the US alone • Drugs for rare kidney diseases can be priced at **~US$120,000 per annum** in the US[3] • There are currently **no approved treatments** available to treat FSGS
Commercial Validation ✓	• **Two commercial licensing deals achieved:** ○ ~AUD$11.5m in upfront payments, ~$340m in potential milestone payments + tiered royalties • Phase 3 interim analysis: **DMX-200 is performing better than placebo** in reducing proteinuria (using a statistical measure[5]) in a significantly larger cohort than DXB prior Phase 2 study
Upcoming FSGS Milestones	• **Execution of potential licensing deals** for available jurisdictions, including the US & China[6] • **Recruitment** and dosing of 144 patients for Part 2 • Part 2 – **second interim analysis** outcome estimated mid-2025

Dimerix

1. Nephcure Understanding FSGS 2022: https://nephcure.org/livingwithkidneydisease/ns-and-other-glomerular-diseases/understanding-fsgs/; 2. Focal segmental glomerulosclerosis – Market Insight (2022), Epidemiology and market forecast – 2032 Delve Insight;; 3. Cost of Sparsentan - approved for IgAN https://endpts.com/fda-clears-traveres-rare-kidney-disease-drug-will-come-with-rems-program; 4. ASX release 05Oct23; 5. Predictive Power statistical model, using industry standard as set by the independent renal biostatistician consultant for Dimerix; 6. Offers are non-binding and subject to due diligence, a definitive agreement and board approval

Dimerix

A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases.

WELL POSITIONED TO DELIVER OUR STRATEGIC PLAN

SCAN ME

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. investor@dimerix.com

ESG Statement
Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve its ESG performance demonstrate a strong, well-informed management attitude and a values led culture that is both alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.